{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:16Z","timestamp":1794007336843,"version":"4.8.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite improvements in treatment and diagnostics over the last two decades, invasive aspergillosis (IA) remains a devastating fungal disease. The number of immunocompromised patients and hence vulnerable hosts increases, which is paralleled by the emergence of a rise in IA cases. Increased frequencies of azole-resistant strains are reported from six continents, presenting a new challenge for the therapeutic management. Treatment options for IA currently consist of three classes of antifungals (azoles, polyenes, echinocandins) with distinctive advantages and shortcomings. Especially in settings of difficult to treat IA, comprising drug tolerance\/resistance, limiting drug\u2013drug interactions, and\/or severe underlying organ dysfunction, novel approaches are urgently needed. Promising new drugs for the treatment of IA are in late-stage clinical development, including olorofim (a dihydroorotate dehydrogenase inhibitor), fosmanogepix (a Gwt1 enzyme inhibitor), ibrexafungerp (a triterpenoid), opelconazole (an azole optimized for inhalation) and rezafungin (an echinocandin with long half-life time). Further, new insights in the pathophysiology of IA yielding immunotherapy as a potential add-on therapy. Current investigations show encouraging results, so far mostly in preclinical settings. In this review we discuss current treatment strategies, give an outlook on possible new pharmaceutical therapeutic options, and, lastly, provide an overview of the ongoing research in immunotherapy for IA.<\/jats:p>","DOI":"10.1007\/s11046-023-00727-z","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:03:32Z","timestamp":1682528612000},"page":"667-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Treatment of Invasive Aspergillosis: How It\u2019s Going, Where It\u2019s Heading"],"prefix":"10.1007","volume":"188","author":[{"given":"Johannes","family":"Boyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-9471","authenticated-orcid":false,"given":"Simon","family":"Feys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zsifkovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7795-4406","authenticated-orcid":false,"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"3","key":"727_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s15010-013-0432-0","volume":"41","author":"MT Montagna","year":"2013","unstructured":"Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013;41(3):645\u201353.","journal-title":"Infection"},{"issue":"8","key":"727_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","volume":"50","author":"PG Pappas","year":"2010","unstructured":"Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101\u201311.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"727_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/myc.13205","volume":"64","author":"L Souza","year":"2021","unstructured":"Souza L, Nouer SA, Morales H, Simoes B, Solza C, Queiroz-Telles F, et al. Epidemiology of invasive fungal disease in haematologic patients. Mycoses. 2021;64(3):252\u20136.","journal-title":"Mycoses"},{"issue":"8","key":"727_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","volume":"7","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127\u201340.","journal-title":"Nat Microbiol"},{"key":"727_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.simyco.2021.100115","volume":"100","author":"A Arastehfar","year":"2021","unstructured":"Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, et al. Aspergillus fumigatus and aspergillosis: from basics to clinics. Stud Mycol. 2021;100: 100115.","journal-title":"Stud Mycol"},{"issue":"6","key":"727_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156566","volume":"11","author":"KS Sun","year":"2016","unstructured":"Sun KS, Tsai CF, Chen SC, Chen YY, Huang WC. Correction: Galactomannan testing and the incidence of invasive pulmonary aspergillosis: a 10-year nationwide population-based study in Taiwan. PLoS ONE. 2016;11(6): e0156566.","journal-title":"PLoS ONE"},{"key":"727_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/5584_2019_347","volume":"1160","author":"P Tarka","year":"2019","unstructured":"Tarka P, Nitsch-Osuch A, Gorynski P, Tyszko P, Bogdan M, Kanecki K. Epidemiology of pulmonary aspergillosis in hospitalized patients in Poland during 2009\u20132016. Adv Exp Med Biol. 2019;1160:73\u201380.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"727_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/ciy181","volume":"67","author":"MD Zilberberg","year":"2018","unstructured":"Zilberberg MD, Nathanson BH, Harrington R, Spalding JR, Shorr AF. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009\u20132013. Clin Infect Dis. 2018;67(5):727\u201335.","journal-title":"Clin Infect Dis"},{"key":"727_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/myc.13449","volume":"65","author":"M Egger","year":"2022","unstructured":"Egger M, Hoenigl M, Thompson GR 3rd, Carvalho A, Jenks JD. Let\u2019s talk about sex characteristics\u2014as a risk factor for invasive fungal diseases. Mycoses. 2022;65:599\u2013612.","journal-title":"Mycoses"},{"issue":"5","key":"727_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ijantimicag.2018.08.004","volume":"52","author":"A Abdolrasouli","year":"2018","unstructured":"Abdolrasouli A, Scourfield A, Rhodes J, Shah A, Elborn JS, Fisher MC, et al. High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre. Int J Antimicrob Agents. 2018;52(5):637\u201342.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"727_CR11","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/jac\/dkv177","volume":"70","author":"J Fuhren","year":"2015","unstructured":"Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015;70(10):2894\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"727_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","volume":"25","author":"PPA Lestrade","year":"2019","unstructured":"Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect. 2019;25(7):799\u2013806.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"727_CR13","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1128\/AAC.01005-16","volume":"60","author":"Y Chen","year":"2016","unstructured":"Chen Y, Lu Z, Zhao J, Zou Z, Gong Y, Qu F, et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus Isolates from China. Antimicrob Agents Chemother. 2016;60(10):5878\u201384.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"727_CR14","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3201\/eid2607.200088","volume":"26","author":"PPA Lestrade","year":"2020","unstructured":"Lestrade PPA, Buil JB, van der Beek MT, Kuijper EJ, van Dijk K, Kampinga GA, et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013\u20132018. Emerg Infect Dis. 2020;26(7):1447\u201355.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"727_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12281-021-00418-6","volume":"15","author":"D Macedo","year":"2021","unstructured":"Macedo D, Leonardelli F, Gamarra S, Garcia-Effron G. Emergence of triazole resistance in Aspergillus spp. in Latin America. Curr Fungal Infect Rep. 2021;15(3):93\u2013103.","journal-title":"Curr Fungal Infect Rep"},{"issue":"1","key":"727_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13756-020-00731-8","volume":"9","author":"S Moin","year":"2020","unstructured":"Moin S, Farooqi J, Jabeen K, Laiq S, Zafar A. Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan. Antimicrob Resist Infect Control. 2020;9(1):62.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"727_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/jac\/dkz534","volume":"75","author":"M Parent-Michaud","year":"2020","unstructured":"Parent-Michaud M, Dufresne PJ, Fournier E, Folch B, Martineau C, Moreira S, et al. Prevalence and mechanisms of azole resistance in clinical isolates of Aspergillus section Fumigati species in a Canadian tertiary care centre, 2000 to 2013. J Antimicrob Chemother. 2020;75(4):849\u201358.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"727_CR18","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.jiac.2021.08.024","volume":"27","author":"A Resendiz-Sharpe","year":"2021","unstructured":"Resendiz-Sharpe A, Merckx R, Verweij PE, Maertens J, Lagrou K. Stable prevalence of triazole-resistance in Aspergillus fumigatus complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. J Infect Chemother. 2021;27(12):1774\u20138.","journal-title":"J Infect Chemother"},{"issue":"4","key":"727_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/myc.13426","volume":"65","author":"M Risum","year":"2022","unstructured":"Risum M, Hare RK, Gertsen JB, Kristensen L, Rosenvinge FS, Sulim S, et al. Azole resistance in Aspergillus fumigatus. The first 2-year\u2019s data from the Danish National Surveillance Study, 2018\u20132020. Mycoses. 2022;65(4):419\u201328.","journal-title":"Mycoses"},{"issue":"9","key":"727_CR20","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1093\/jac\/dky187","volume":"73","author":"JJ Talbot","year":"2018","unstructured":"Talbot JJ, Subedi S, Halliday CL, Hibbs DE, Lai F, Lopez-Ruiz FJ, et al. Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates. J Antimicrob Chemother. 2018;73(9):2347\u201351.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"727_CR21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3201\/eid2106.140717","volume":"21","author":"JW van der Linden","year":"2015","unstructured":"van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041\u20134.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"727_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/mmy\/myz003","volume":"57","author":"Y Tsuchido","year":"2019","unstructured":"Tsuchido Y, Tanaka M, Nakano S, Yamamoto M, Matsumura Y, Nagao M. Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34\/L98H mutation in the Kyoto and Shiga regions of Japan. Med Mycol. 2019;57(8):997\u20131003.","journal-title":"Med Mycol"},{"key":"727_CR23","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.939088","volume":"28","author":"DV Parums","year":"2022","unstructured":"Parums DV. Editorial: The World Health Organization (WHO) fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic. Med Sci Monit. 2022;28: e939088.","journal-title":"Med Sci Monit"},{"issue":"4","key":"727_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0891-5520(02)00035-1","volume":"16","author":"KA Marr","year":"2002","unstructured":"Marr KA, Patterson T, Denning D. Aspergillosis\u2014pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N Am. 2002;16(4):875.","journal-title":"Infect Dis Clin N Am."},{"issue":"9","key":"727_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13544","volume":"33","author":"S Husain","year":"2019","unstructured":"Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9): e13544.","journal-title":"Clin Transplant"},{"issue":"4","key":"727_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"727_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"727_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"727_CR29","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/pharmaceutics13111961","volume":"13","author":"A Czyrski","year":"2021","unstructured":"Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka FK. The Overview on the pharmacokinetic and pharmacodynamic interactions of triazoles. Pharmaceutics. 2021;13(11):1961.","journal-title":"Pharmaceutics"},{"issue":"2","key":"727_CR30","first-page":"149","volume":"16","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"727_CR31","doi-asserted-by":"publisher","first-page":"e00392","DOI":"10.1128\/mBio.00392-19","volume":"10","author":"TR Sewell","year":"2019","unstructured":"Sewell TR, Zhu J, Rhodes J, Hagen F, Meis JF, Fisher MC, et al. Nonrandom distribution of azole resistance across the global population of Aspergillus fumigatus. MBio. 2019;10(3):e00392-e419.","journal-title":"MBio"},{"issue":"15","key":"727_CR32","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703\u201329.","journal-title":"Drugs"},{"key":"727_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.732223","volume":"11","author":"TP McCarty","year":"2021","unstructured":"McCarty TP, Pappas PG. Antifungal pipeline. Front Cell Infect Microbiol. 2021;11: 732223.","journal-title":"Front Cell Infect Microbiol"},{"key":"727_CR34","doi-asserted-by":"crossref","unstructured":"Husain S. CJF. Invasive Aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. 2019(Special Issue: Transplant Infectious Diseases).","DOI":"10.1111\/ctr.13544"},{"key":"727_CR35","unstructured":"Patterson TF. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. 2016(IDSA Guideline)."},{"issue":"8","key":"727_CR36","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/jac\/dkw111","volume":"71","author":"F Barchiesi","year":"2016","unstructured":"Barchiesi F, Santinelli A, Biscotti T, Greganti G, Giannini D, Manso E. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection. J Antimicrob Chemother. 2016;71(8):2230\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"727_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","volume":"31","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Fl\u00f6rl C, Bellmann R, et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022;31:795\u2013812.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"727_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/jof8080857","volume":"8","author":"NP Wiederhold","year":"2022","unstructured":"Wiederhold NP. Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J Fungi (Basel). 2022;8(8):857.","journal-title":"J Fungi (Basel)."},{"issue":"4","key":"727_CR39","doi-asserted-by":"publisher","first-page":"e02542","DOI":"10.1128\/AAC.02542-17","volume":"62","author":"M Zhao","year":"2018","unstructured":"Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother. 2018;62(4):e02542-e2617.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"727_CR40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/jof8111121","volume":"8","author":"DA Angulo","year":"2022","unstructured":"Angulo DA, Alexander B, Rautemaa-Richardson R, Alastruey-Izquierdo A, Hoenigl M, Ibrahim AS, et al. Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections. J Fungi (Basel). 2022;8(11):1121.","journal-title":"J Fungi (Basel)."},{"issue":"1","key":"727_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.690","volume":"9","author":"L Cass","year":"2021","unstructured":"Cass L, Murray A, Davis A, Woodward K, Albayaty M, Ito K, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect. 2021;9(1): e00690.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"727_CR42","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","volume":"61","author":"T Sandison","year":"2017","unstructured":"Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2):e01627-e1716.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"727_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/jof4030098","volume":"4","author":"JD Jenks","year":"2018","unstructured":"Jenks JD, Hoenigl M. Treatment of Aspergillosis. J Fungi (Basel, Switzerland). 2018;4(3):98. https:\/\/doi.org\/10.3390\/jof4030098.","journal-title":"J Fungi (Basel, Switzerland)"},{"key":"727_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R. Voriconazole versus ampthotericin B for primary therapy of invasive aspergillosis. New Engl J Med. 2002;347:408\u201315.","journal-title":"New Engl J Med."},{"key":"727_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2015","unstructured":"Maertens JA. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2015;387:760\u20139.","journal-title":"Lancet"},{"issue":"10273","key":"727_CR46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG, Ponce-de-Le\u00f3n A, Ram\u00edrez S\u00e1nchez IC, Klimko N, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509.","journal-title":"Lancet"},{"issue":"5","key":"727_CR47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563\u201371.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"727_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/13693786.2012.690108","volume":"51","author":"JW Baddley","year":"2013","unstructured":"Baddley JW, Andes DR, Marr KA, Kauffman CA, Kontoyiannis DP, Ito JI, et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol. 2013;51(2):128\u201335.","journal-title":"Med Mycol"},{"issue":"3","key":"727_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s15010-011-0108-6","volume":"39","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection. 2011;39(3):201\u201310.","journal-title":"Infection"},{"issue":"7","key":"727_CR50","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"727_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.medmal.2011.09.016","volume":"41","author":"O Epaulard","year":"2011","unstructured":"Epaulard O, Leccia MT, Blanche S, Chosidow O, Mamzer-Bruneel MF, Ravaud P, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect. 2011;41(12):639\u201345.","journal-title":"Med Mal Infect"},{"issue":"1","key":"727_CR52","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1086\/588844","volume":"47","author":"DI Zonios","year":"2008","unstructured":"Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47(1):e7\u201310.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"727_CR53","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","volume":"71","author":"H Jin","year":"2016","unstructured":"Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"727_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ. Diagnosis and management of Aspergillus disease: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1\u201338.","journal-title":"Clin Microbiol Infect"},{"key":"727_CR55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F. ECIL-6 guidelines for the treatment of invasive candidiasis, Aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433.","journal-title":"Haematologica"},{"issue":"7","key":"727_CR56","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1128\/AAC.00251-13","volume":"57","author":"M Hoenigl","year":"2013","unstructured":"Hoenigl M, Duettmann W, Raggam RB, Seeber K, Troppan K, Fruhwald S, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"727_CR57","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","volume":"57","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(2):S168\u201378.","journal-title":"Med Mycol"},{"issue":"2","key":"727_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof6020090","volume":"6","author":"C Zurl","year":"2020","unstructured":"Zurl C, Waller M, Schwameis F, Muhr T, Bauer N, Zollner-Schwetz I, et al. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations. J Fungi (Basel). 2020;6(2):90.","journal-title":"J Fungi (Basel)."},{"key":"727_CR59","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/DDDT.S145545","volume":"12","author":"JD Jenks","year":"2018","unstructured":"Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Dev Ther. 2018;12:1033\u201344.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"727_CR60","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1093\/jac\/dkac196","volume":"77","author":"L Kriegl","year":"2022","unstructured":"Kriegl L, Hatzl S, Zurl C, Reisinger AC, Schilcher G, Eller P, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022;77(9):2500\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"727_CR61","doi-asserted-by":"publisher","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","volume":"62","author":"D Andes","year":"2018","unstructured":"Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob Agents Chemother. 2018;62(7):e00585-e618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"727_CR62","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","volume":"74","author":"E Furfaro","year":"2019","unstructured":"Furfaro E, Signori A, Di Grazia C, Dominietto A, Raiola AM, Aquino S, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019;74(8):2341\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"727_CR63","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","volume":"26","author":"A Gomez-Lopez","year":"2020","unstructured":"Gomez-Lopez A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"727_CR64","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","volume":"65","author":"R Hohl","year":"2022","unstructured":"Hohl R, Bertram R, Kinzig M, Haarmeyer GS, Baumgartel M, Geise A, et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022;65(7):747\u201352.","journal-title":"Mycoses"},{"issue":"5","key":"727_CR65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","volume":"10","author":"M Risum","year":"2021","unstructured":"Risum M, Vestergaard MB, Weinreich UM, Helleberg M, Vissing NH, Jorgensen R. Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole. Antibiotics (Basel). 2021;10(5):487.","journal-title":"Antibiotics (Basel)."},{"issue":"9","key":"727_CR66","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","volume":"62","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Hoenigl M, Lass-Florl C, Chen SC, Kontoyiannis DP, Morrissey CO, et al. Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019;62(9):716\u201329.","journal-title":"Mycoses"},{"key":"727_CR67","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"A Ullmann","year":"2018","unstructured":"Ullmann A, Aguado JM, Arikan S, Denning D, Groll A, Lagrou K, et al. Executive summary of the 2017 ESCMID-ECMM guideline for the diagnosis and management of Aspergillus disease. Clin Microb Infect. 2018;24:e1\u201338.","journal-title":"Clin Microb Infect."},{"issue":"1","key":"727_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/myc.13020","volume":"63","author":"J Oh","year":"2020","unstructured":"Oh J, Kang CI, Kim SH, Huh K, Cho SY, Chung DR, et al. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: therapeutic drug monitoring, efficacy and risk factors for the suboptimal level. Mycoses. 2020;63(1):89\u201394.","journal-title":"Mycoses"},{"issue":"3","key":"727_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/myc.12724","volume":"61","author":"D Stelzer","year":"2018","unstructured":"Stelzer D, Weber A, Ihle F, Matthes S, Ceelen F, Zimmermann G, et al. Posaconazole liquid versus tablet formulation in lung transplant recipients. Mycoses. 2018;61(3):186\u201394.","journal-title":"Mycoses"},{"key":"727_CR70","doi-asserted-by":"publisher","first-page":"e02655","DOI":"10.1128\/AAC.02655-17","volume":"62","author":"D Lenczuk","year":"2018","unstructured":"Lenczuk D, Zinke-Cerwenka W, Greinix H, Wolfler A, Prattes J, Zollner-Schwetz I, et al. Antifungal prophylaxis with Posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy and tolerability. Antimicrobial Agents Chemother. 2018;62:e02655-e2717.","journal-title":"Antimicrobial Agents Chemother"},{"issue":"2","key":"727_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijantimicag.2014.03.013","volume":"44","author":"M Hoenigl","year":"2014","unstructured":"Hoenigl M, Duettmann W, Raggam RB, Huber-Krassnitzer B, Theiler G, Seeber K, et al. Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. Int J Antimicrob Agents. 2014;44(2):140\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"727_CR72","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1128\/AAC.00389-16","volume":"60","author":"J Prattes","year":"2016","unstructured":"Prattes J, Duettmann W, Hoenigl M. Posaconazole plasma concentrations on days three to five predict steady-state levels. Antimicrob Agents Chemother. 2016;60(9):5595\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"727_CR73","first-page":"3221","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221\u201330.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"727_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1592\/phco.30.8.842","volume":"30","author":"E Dodds-Ashley","year":"2010","unstructured":"Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30(8):842\u201354.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"727_CR75","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","volume":"9","author":"RJ Bruggemann","year":"2022","unstructured":"Bruggemann RJ, Verheggen R, Boerrigter E, Stanzani M, Verweij PE, Blijlevens NMA, et al. Management of drug\u2013drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematol. 2022;9(1):e58\u201372.","journal-title":"Lancet Haematol"},{"issue":"1","key":"727_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56(1):24\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"727_CR77","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1517\/17425255.2014.883379","volume":"10","author":"RK Vadlapatla","year":"2014","unstructured":"Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug\u2013drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014;10(4):561\u201380.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"727_CR78","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919\u201334.","journal-title":"Drugs"},{"issue":"6","key":"727_CR79","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cncr.23311","volume":"112","author":"RY Hachem","year":"2008","unstructured":"Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112(6):1282\u20137.","journal-title":"Cancer"},{"issue":"2","key":"727_CR80","doi-asserted-by":"publisher","first-page":"ii21","DOI":"10.1093\/jac\/dkac353","volume":"77","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Lewis R, van de Veerdonk FL, Verweij PE, Cornely OA. Liposomal amphotericin B-the future. J Antimicrob Chemother. 2022;77(2):ii21\u201334.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"727_CR81","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/myc.12585","volume":"60","author":"LM Steimbach","year":"2017","unstructured":"Steimbach LM, Tonin FS, Virtuoso S, Borba HH, Sanches AC, Wiens A, et al. Efficacy and safety of amphotericin B lipid-based formulations-a systematic review and meta-analysis. Mycoses. 2017;60(3):146\u201354.","journal-title":"Mycoses"},{"issue":"10","key":"727_CR82","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289\u201397.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"727_CR83","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1086\/515033","volume":"27","author":"M Ellis","year":"1998","unstructured":"Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27(6):1406\u201312.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"727_CR84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","volume":"28","author":"V Monforte","year":"2009","unstructured":"Monforte V, Ussetti P, L\u00f3pez R, Gavald\u00e0 J, Bravo C, de Pablo A, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170\u20135.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"727_CR85","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","volume":"29","author":"V Monforte","year":"2010","unstructured":"Monforte V, Ussetti P, Gavald\u00e0 J, Bravo C, Laporta R, Len O, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant. 2010;29(5):523\u201330.","journal-title":"J Heart Lung Transplant"},{"key":"727_CR86","doi-asserted-by":"publisher","first-page":"117863611986993","DOI":"10.1177\/1178636119869937","volume":"12","author":"MJ Duckwall","year":"2019","unstructured":"Duckwall MJ, Gales MA, Gales BJ. Inhaled amphotericin B as Aspergillosis prophylaxis in hematologic disease: an update. Microbiol Insights. 2019;12:1178636119869937.","journal-title":"Microbiol Insights"},{"key":"727_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","volume":"21\u201322","author":"PE Verweij","year":"2015","unstructured":"Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Bruggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Update. 2015;21\u201322:30\u201340.","journal-title":"Drug Resist Update"},{"issue":"7","key":"727_CR88","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2009.334","volume":"45","author":"R Herbrecht","year":"2010","unstructured":"Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 2010;45(7):1227\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"727_CR89","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1128\/AAC.05134-11","volume":"55","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Vehreschild JJ, Vehreschild MJ, W\u00fcrthwein G, Arenz D, Schwartz S, et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother. 2011;55(12):5798\u2013803.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"727_CR90","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jac\/dkp355","volume":"64","author":"C Viscoli","year":"2009","unstructured":"Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, et al. An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64(6):1274\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"727_CR91","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","volume":"68","author":"DA Enoch","year":"2014","unstructured":"Enoch DA, Idris SF, Aliyu SH, Micallef C, Sule O, Karas JA. Micafungin for the treatment of invasive aspergillosis. J Infect. 2014;68(6):507\u201326.","journal-title":"J Infect"},{"issue":"3","key":"727_CR92","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1592\/phco.27.3.369","volume":"27","author":"D Cappelletty","year":"2007","unstructured":"Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27(3):369\u201388.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"727_CR93","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","volume":"162","author":"KA Marr","year":"2015","unstructured":"Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81\u20139.","journal-title":"Ann Intern Med"},{"key":"727_CR94","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/myc.12788","volume":"61","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Bruggemann RJ, Biemond BJ, et al. The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. Mycoses. 2018;61:656\u201364.","journal-title":"Mycoses"},{"issue":"7","key":"727_CR95","doi-asserted-by":"publisher","first-page":"e00275","DOI":"10.1128\/AAC.00275-20","volume":"64","author":"J Marx","year":"2020","unstructured":"Marx J, Welte R, Gasperetti T, Moser P, Beer R, Ortler M, et al. Anidulafungin and micafungin concentrations in cerebrospinal fluid and in cerebral cortex. Antimicrob Agents Chemother. 2020;64(7):e00275-e320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"727_CR96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.idc.2021.03.005","volume":"35","author":"MD Johnson","year":"2021","unstructured":"Johnson MD. Antifungals in clinical use and the pipeline. Infect Dis Clin North Am. 2021;35(2):341\u201371.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"727_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","volume":"46","author":"A Vermes","year":"2000","unstructured":"Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"727_CR98","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jof7050378","volume":"7","author":"O Georgacopoulos","year":"2021","unstructured":"Georgacopoulos O, Nunnally NS, Ransom EM, Law D, Birch M, Lockhart SR, et al. In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents. J Fungi (Basel). 2021;7(5):378.","journal-title":"J Fungi (Basel)."},{"issue":"3","key":"727_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106105","volume":"56","author":"L Kirchhoff","year":"2020","unstructured":"Kirchhoff L, Dittmer S, Buer J, Rath PM, Steinmann J. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56(3): 106105.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"727_CR100","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00380-22","volume":"66","author":"T Gebremariam","year":"2022","unstructured":"Gebremariam T, Gu Y, Alkhazraji S, Youssef E, Shaw KJ, Ibrahim AS. The combination treatment of fosmanogepix and liposomal Amphotericin B is superior to monotherapy in treating experimental invasive mold infections. Antimicrob Agents Chemother. 2022;66(7): e0038022.","journal-title":"Antimicrob Agents Chemother"},{"key":"727_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofaa439.457","volume":"7","author":"PKB Pappas","year":"2020","unstructured":"Pappas PKB, Vazquez JA, Oren I, Rahav G, Aoun M, Bulpa P, Ben-Ami R, Ferrer R, McCarty TP, Thompson GR III, Barbat S, Wedel P, Oborska I, Schlamm HT, Hodges M. Clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of candidemia: results from a phase 2 proof of concept trial. Open Forum Infect Dis. 2020;7:1.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"727_CR102","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/jof7030232","volume":"7","author":"O Rivero-Menendez","year":"2021","unstructured":"Rivero-Menendez O, Soto-Debran JC, Cuenca-Estrella M, Alastruey-Izquierdo A. In Vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J Fungi (Basel). 2021;7(3):232.","journal-title":"J Fungi (Basel)."},{"issue":"1","key":"727_CR103","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1038\/s41598-019-45890-w","volume":"9","author":"T Colley","year":"2019","unstructured":"Colley T, Sehra G, Daly L, Kimura G, Nakaoki T, Nishimoto Y, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci Rep. 2019;9(1):9482.","journal-title":"Sci Rep"},{"issue":"6","key":"727_CR104","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1086\/314493","volume":"178","author":"E Cenci","year":"1998","unstructured":"Cenci E, Mencacci A, Fe d\u2019Ostiani C, Del Sero G, Mosci P, Montagnoli C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis. 1998;178(6):1750\u201360.","journal-title":"J Infect Dis"},{"issue":"13","key":"727_CR105","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1182\/blood-2002-01-0265","volume":"100","author":"H Hebart","year":"2002","unstructured":"Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100(13):4521\u20138.","journal-title":"Blood"},{"issue":"3","key":"727_CR106","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1128\/IAI.69.3.1554-1560.2001","volume":"69","author":"JK Brieland","year":"2001","unstructured":"Brieland JK, Jackson C, Menzel F, Loebenberg D, Cacciapuoti A, Halpern J, et al. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun. 2001;69(3):1554\u201360.","journal-title":"Infect Immun"},{"issue":"1","key":"727_CR107","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2567.2009.03211.x","volume":"130","author":"LY Chai","year":"2010","unstructured":"Chai LY, van de Veerdonk F, Marijnissen RJ, Cheng SC, Khoo AL, Hectors M, et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology. 2010;130(1):46\u201354.","journal-title":"Immunology"},{"issue":"1","key":"727_CR108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1099\/0022-1317-51-1-70","volume":"51","author":"M Ellis","year":"2002","unstructured":"Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol. 2002;51(1):70\u20135.","journal-title":"J Med Microbiol"},{"issue":"4","key":"727_CR109","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s15010-008-7378-7","volume":"36","author":"A Bandera","year":"2008","unstructured":"Bandera A, Trabattoni D, Ferrario G, Cesari M, Franzetti F, Clerici M, et al. Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis. Infection. 2008;36(4):368\u201373.","journal-title":"Infection"},{"issue":"8","key":"727_CR110","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/j.1600-6143.2010.03094.x","volume":"10","author":"D Armstrong-James","year":"2010","unstructured":"Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A, et al. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant. 2010;10(8):1796\u2013803.","journal-title":"Am J Transplant"},{"key":"727_CR111","volume":"2012","author":"C Estrada","year":"2012","unstructured":"Estrada C, Desai AG, Chirch LM, Suh H, Seidman R, Darras F, et al. Invasive aspergillosis in a renal transplant recipient successfully treated with interferon-gamma. Case Rep Transplant. 2012;2012: 493758.","journal-title":"Case Rep Transplant"},{"issue":"12","key":"727_CR112","first-page":"1359","volume":"80","author":"M Mezidi","year":"2014","unstructured":"Mezidi M, Belafia F, Nougaret S, Pageaux GP, Conseil M, Panaro F, et al. Interferon gamma in association with immunosuppressive drugs withdrawal and antifungal combination as a rescue therapy for cerebral invasive Aspergillosis in a liver transplant recipient. Minerva Anestesiol. 2014;80(12):1359\u201360.","journal-title":"Minerva Anestesiol"},{"key":"727_CR113","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","volume":"14","author":"CE Delsing","year":"2014","unstructured":"Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"727_CR114","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/SHK.0000000000001392","volume":"53","author":"CTB Vu","year":"2020","unstructured":"Vu CTB, Thammahong A, Yagita H, Azuma M, Hirankarn N, Ritprajak P, et al. Blockade Of PD-1 attenuated postsepsis aspergillosis via the activation of IFN-\u03b3 and the dampening of IL-10. Shock. 2020;53(4):514\u201324.","journal-title":"Shock"},{"issue":"6","key":"727_CR115","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/infdis\/jiaa264","volume":"222","author":"S Wurster","year":"2020","unstructured":"Wurster S, Robinson P, Albert ND, Tarrand JJ, Goff M, Swamydas M, et al. Protective activity of programmed cell death protein 1 blockade and synergy with caspofungin in a murine invasive pulmonary aspergillosis model. J Infect Dis. 2020;222(6):989\u201394.","journal-title":"J Infect Dis"},{"key":"727_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900522","volume":"13","author":"A Serris","year":"2022","unstructured":"Serris A, Ouedrani A, Uhel F, Gazzano M, Bedarida V, Rouzaud C, et al. Case report: immune checkpoint blockade plus interferon-\u03b3 add-on antifungal therapy in the treatment of refractory covid-associated pulmonary Aspergillosis and cerebral mucormycosis. Front Immunol. 2022;13: 900522.","journal-title":"Front Immunol"},{"key":"727_CR117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mmcr.2022.06.003","volume":"37","author":"AC Lukaszewicz","year":"2022","unstructured":"Lukaszewicz AC, Venet F, Boibieux A, Lherm M, Devigne B, Monneret G. Nivolumab and interferon-\u03b3 rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock. Med Mycol Case Rep. 2022;37:19\u201322.","journal-title":"Med Mycol Case Rep"},{"issue":"10","key":"727_CR118","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/infdis\/jiab583","volume":"225","author":"SAP Colombo","year":"2022","unstructured":"Colombo SAP, Hashad R, Denning DW, Kumararatne DS, Ceron-Gutierrez L, Barcenas-Morales G, et al. Defective interferon-gamma production is common in chronic pulmonary Aspergillosis. J Infect Dis. 2022;225(10):1822\u201331.","journal-title":"J Infect Dis"},{"issue":"6","key":"727_CR119","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/thoraxjnl-2019-213606","volume":"75","author":"EJM Monk","year":"2020","unstructured":"Monk EJM, Harris C, D\u00f6ffinger R, Hayes G, Denning DW, Kosmidis C. Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission. Thorax. 2020;75(6):513\u20136.","journal-title":"Thorax"},{"issue":"8","key":"727_CR120","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/infdis\/jiw054","volume":"213","author":"S Kasahara","year":"2016","unstructured":"Kasahara S, Jhingran A, Dhingra S, Salem A, Cramer RA, Hohl TM. Role of granulocyte-macrophage colony-stimulating factor signaling in regulating neutrophil antifungal activity and the oxidative burst during respiratory fungal challenge. J Infect Dis. 2016;213(8):1289\u201398.","journal-title":"J Infect Dis"},{"issue":"1","key":"727_CR121","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/jinf.2000.0673","volume":"41","author":"L Abu Jawdeh","year":"2000","unstructured":"Abu Jawdeh L, Haidar R, Bitar F, Mroueh S, Akel S, Nuwayri-Salti N, et al. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy. J Infect. 2000;41(1):97\u2013100.","journal-title":"J Infect"},{"issue":"11","key":"727_CR122","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/thx.54.11.1047","volume":"54","author":"RJ Boots","year":"1999","unstructured":"Boots RJ, Paterson DL, Allworth AM, Faoagali JL. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax. 1999;54(11):1047\u20139.","journal-title":"Thorax"},{"issue":"34","key":"727_CR123","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1200\/JCO.2014.60.5121","volume":"33","author":"L Wan","year":"2015","unstructured":"Wan L, Zhang Y, Lai Y, Jiang M, Song Y, Zhou J, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial. J Clin Oncol. 2015;33(34):3999\u20134006.","journal-title":"J Clin Oncol"},{"issue":"6912","key":"727_CR124","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature01195","volume":"420","author":"C Garlanda","year":"2002","unstructured":"Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420(6912):182\u20136.","journal-title":"Nature"},{"issue":"7","key":"727_CR125","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.4049\/jimmunol.0900345","volume":"183","author":"C D'Angelo","year":"2009","unstructured":"D\u2019Angelo C, De Luca A, Zelante T, Bonifazi P, Moretti S, Giovannini G, et al. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol. 2009;183(7):4609\u201318.","journal-title":"J Immunol"},{"issue":"11","key":"727_CR126","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1128\/AAC.48.11.4414-4421.2004","volume":"48","author":"R Gaziano","year":"2004","unstructured":"Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L, et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother. 2004;48(11):4414\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"727_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcsw.2022.100072","volume":"8","author":"SSW Wong","year":"2022","unstructured":"Wong SSW, Delli\u00e8re S, Schiefermeier-Mach N, Lechner L, Perkhofer S, Bomme P, et al. Surfactant protein D inhibits growth, alters cell surface polysaccharide exposure and immune activation potential of Aspergillus fumigatus. Cell Surf. 2022;8: 100072.","journal-title":"Cell Surf"},{"issue":"11","key":"727_CR128","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1182\/blood.V95.11.3302.010k35_3302_3309","volume":"95","author":"TH Price","year":"2000","unstructured":"Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, et al. Phase I\/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95(11):3302\u20139.","journal-title":"Blood"},{"issue":"10","key":"727_CR129","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2008.237","volume":"42","author":"MG Seidel","year":"2008","unstructured":"Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42(10):679\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"727_CR130","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","volume":"106","author":"K Perruccio","year":"2005","unstructured":"Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397\u2013406.","journal-title":"Blood"},{"issue":"664","key":"727_CR131","doi-asserted-by":"publisher","first-page":"eabh1209","DOI":"10.1126\/scitranslmed.abh1209","volume":"14","author":"M Seif","year":"2022","unstructured":"Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med. 2022;14(664):eabh1209.","journal-title":"Sci Transl Med."},{"issue":"1","key":"727_CR132","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4049\/jimmunol.165.1.381","volume":"165","author":"E Cenci","year":"2000","unstructured":"Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000;165(1):381\u20138.","journal-title":"J Immunol"},{"issue":"9","key":"727_CR133","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1128\/IAI.00815-06","volume":"74","author":"JI Ito","year":"2006","unstructured":"Ito JI, Lyons JM, Hong TB, Tamae D, Liu YK, Wilczynski SP, et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun. 2006;74(9):5075\u201384.","journal-title":"Infect Immun"},{"issue":"4","key":"727_CR134","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.4049\/jimmunol.0900961","volume":"183","author":"S Bozza","year":"2009","unstructured":"Bozza S, Clavaud C, Giovannini G, Fontaine T, Beauvais A, Sarfati J, et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol. 2009;183(4):2407\u201314.","journal-title":"J Immunol"},{"issue":"8","key":"727_CR135","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3109\/13693786.2012.683539","volume":"50","author":"M Liu","year":"2012","unstructured":"Liu M, Machov\u00e1 E, Ne\u0161\u010d\u00e1kov\u00e1 Z, Medovarsk\u00e1 I, Clemons KV, Martinez M, et al. Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol. 2012;50(8):818\u201328.","journal-title":"Med Mycol"},{"issue":"4","key":"727_CR136","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/jof4040137","volume":"4","author":"CD Lauruschkat","year":"2018","unstructured":"Lauruschkat CD, Einsele H, Loeffler J. Immunomodulation as a therapy for Aspergillus infection: current status and future perspectives. J Fungi (Basel). 2018;4(4):137.","journal-title":"J Fungi (Basel)."},{"issue":"6","key":"727_CR137","doi-asserted-by":"publisher","first-page":"e02145","DOI":"10.1128\/mBio.02145-19","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang K, Masso-Silva JA, Rivera A, Xue C. A heat-killed cryptococcus mutant strain induces host protection against multiple invasive mycoses in a murine vaccine model. MBio. 2019;10(6):e02145-e2219.","journal-title":"MBio"},{"key":"727_CR138","doi-asserted-by":"publisher","first-page":"670578","DOI":"10.3389\/fimmu.2021.670578","volume":"12","author":"E Rayens","year":"2021","unstructured":"Rayens E, Rabacal W, Kang SE, Celia BN, Momany M, Norris KA. Vaccine-induced protection in two murine models of invasive pulmonary Aspergillosis. Front Immunol. 2021;12:670578.","journal-title":"Front Immunol"},{"issue":"5","key":"727_CR139","doi-asserted-by":"publisher","first-page":"e0232822","DOI":"10.1128\/mbio.02328-22","volume":"13","author":"CM Fernandes","year":"2022","unstructured":"Fernandes CM, Normile TG, Fabri J, Brauer VS, de Sraujo GR, Frases S, et al. Vaccination with live or heat-killed Aspergillus fumigatus \u0394sglA conidia fully protects immunocompromised mice from invasive Aspergillosis. MBio. 2022;13(5):e0232822.","journal-title":"MBio"},{"issue":"12","key":"727_CR140","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","volume":"10","author":"S Feys","year":"2022","unstructured":"Feys S, Gon\u00e7alves SM, Khan M, Choi S, Boeckx B, Chatelain D, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med. 2022;10(12):1147\u201359.","journal-title":"Lancet Respir Med"},{"issue":"674","key":"727_CR141","doi-asserted-by":"publisher","first-page":"eabq6682","DOI":"10.1126\/scitranslmed.abq6682","volume":"14","author":"N Sarden","year":"2022","unstructured":"Sarden N, Sinha S, Potts KG, Pernet E, Hiroki CH, Hassanabad MF, et al. A B1a-natural IgG-neutrophil axis is impaired in viral- and steroid-associated aspergillosis. Sci Transl Med. 2022;14(674):eabq6682.","journal-title":"Sci Transl Med."},{"key":"727_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954985","volume":"13","author":"B Tappe","year":"2022","unstructured":"Tappe B, Lauruschkat CD, Strobel L, Pantale\u00f3n Garc\u00eda J, Kurzai O, Rebhan S, et al. COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds. Front Immunol. 2022;13: 954985.","journal-title":"Front Immunol"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-023-00727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-023-00727-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-023-00727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:12:56Z","timestamp":1696939976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-023-00727-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":142,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s11046-023-00727-z","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SF received travel grants from Pfizer. MH received research funding from Gilead, Astellas, MSD, Mundipharma, Euroimmune, Scynexis, F2G and Pfizer. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}